Obesity management is evolving with the integration of digital and pharmacological innovations. Continuous Glucose Monitoring (CGM) offers dynamic insights into glucose variability, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, demonstrate potent weight loss and glycaemic control - even in non-diabetic populations. The synergy of CGM and GLP-1RAs enables personalised treatment by capturing real-time metabolic responses, with CGM offering behavioural feedback and GLP-1 RAs addressing hyperinsulinaemia and appetite dysregulation. Yet, no randomised controlled trials have assessed their combined use in obesity without diabetes, representing a critical evidence gap. Furthermore, CGM-derived metrics remain unstandardised in this context, limiting their interpretive value. Looking ahead, AI-driven CGM analysis could predict individual responsiveness to therapy, refining interventions and supporting long-term metabolic health. Together, these tools offer a promising path to breaking the cycle of insulin resistance and obesity.